These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

183 related items for PubMed ID: 20870149

  • 1. Anti-EGFRvIII monoclonal antibody armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Hens M, Vaidyanathan G, Zhao XG, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2010 Oct; 37(7):741-50. PubMed ID: 20870149
    [Abstract] [Full Text] [Related]

  • 2. Labeling internalizing anti-epidermal growth factor receptor variant III monoclonal antibody with (177)Lu: in vitro comparison of acyclic and macrocyclic ligands.
    Hens M, Vaidyanathan G, Welsh P, Zalutsky MR.
    Nucl Med Biol; 2009 Feb; 36(2):117-28. PubMed ID: 19217523
    [Abstract] [Full Text] [Related]

  • 3.
    Chopra A.
    ; 2004 Feb. PubMed ID: 21348055
    [Abstract] [Full Text] [Related]

  • 4.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 5.
    Chopra A.
    ; 2004 Feb. PubMed ID: 21348053
    [Abstract] [Full Text] [Related]

  • 6.
    Chopra A.
    ; 2004 Feb. PubMed ID: 21348052
    [Abstract] [Full Text] [Related]

  • 7.
    Chopra A.
    ; 2004 Feb. PubMed ID: 21348054
    [Abstract] [Full Text] [Related]

  • 8. Antitenascin antibody 81C6 armed with 177Lu: in vivo comparison of macrocyclic and acyclic ligands.
    Yordanov AT, Hens M, Pegram C, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2007 Feb; 34(2):173-83. PubMed ID: 17307125
    [Abstract] [Full Text] [Related]

  • 9. In vivo comparison of macrocyclic and acyclic ligands for radiolabeling of monoclonal antibodies with 177Lu for radioimmunotherapeutic applications.
    Milenic DE, Garmestani K, Chappell LL, Dadachova E, Yordanov A, Ma D, Schlom J, Brechbiel MW.
    Nucl Med Biol; 2002 May; 29(4):431-42. PubMed ID: 12031878
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11. Improved xenograft targeting of tumor-specific anti-epidermal growth factor receptor variant III antibody labeled using N-succinimidyl 4-guanidinomethyl-3-iodobenzoate.
    Vaidyanathan G, Affleck DJ, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2002 Jan; 29(1):1-11. PubMed ID: 11786270
    [Abstract] [Full Text] [Related]

  • 12. Radioiodination via D-amino acid peptide enhances cellular retention and tumor xenograft targeting of an internalizing anti-epidermal growth factor receptor variant III monoclonal antibody.
    Foulon CF, Reist CJ, Bigner DD, Zalutsky MR.
    Cancer Res; 2000 Aug 15; 60(16):4453-60. PubMed ID: 10969792
    [Abstract] [Full Text] [Related]

  • 13. 90Y-DOTA-hLL2: an agent for radioimmunotherapy of non-Hodgkin's lymphoma.
    Griffiths GL, Govindan SV, Sharkey RM, Fisher DR, Goldenberg DM.
    J Nucl Med; 2003 Jan 15; 44(1):77-84. PubMed ID: 12515879
    [Abstract] [Full Text] [Related]

  • 14. SIB-DOTA: a trifunctional prosthetic group potentially amenable for multi-modal labeling that enhances tumor uptake of internalizing monoclonal antibodies.
    Vaidyanathan G, White BJ, Affleck DJ, Zhao XG, Welsh PC, McDougald D, Choi J, Zalutsky MR.
    Bioorg Med Chem; 2012 Dec 15; 20(24):6929-39. PubMed ID: 23159039
    [Abstract] [Full Text] [Related]

  • 15. AAZTA5-squaramide ester competing with DOTA-, DTPA- and CHX-A″-DTPA-analogues: Promising tool for 177Lu-labeling of monoclonal antibodies under mild conditions.
    Klasen B, Moon ES, Rösch F.
    Nucl Med Biol; 2021 Dec 15; 96-97():80-93. PubMed ID: 33839678
    [Abstract] [Full Text] [Related]

  • 16. Optimization of radioimmunotherapy of renal cell carcinoma: labeling of monoclonal antibody cG250 with 131I, 90Y, 177Lu, or 186Re.
    Brouwers AH, van Eerd JE, Frielink C, Oosterwijk E, Oyen WJ, Corstens FH, Boerman OC.
    J Nucl Med; 2004 Feb 15; 45(2):327-37. PubMed ID: 14960657
    [Abstract] [Full Text] [Related]

  • 17. Panitumumab Modified with Metal-Chelating Polymers (MCP) Complexed to 111In and 177Lu-An EGFR-Targeted Theranostic for Pancreatic Cancer.
    Aghevlian S, Lu Y, Winnik MA, Hedley DW, Reilly RM.
    Mol Pharm; 2018 Mar 05; 15(3):1150-1159. PubMed ID: 29314858
    [Abstract] [Full Text] [Related]

  • 18. Dual-Receptor-Targeted Radioimmunotherapy of Human Breast Cancer Xenografts in Athymic Mice Coexpressing HER2 and EGFR Using 177Lu- or 111In-Labeled Bispecific Radioimmunoconjugates.
    Razumienko EJ, Chen JC, Cai Z, Chan C, Reilly RM.
    J Nucl Med; 2016 Mar 05; 57(3):444-52. PubMed ID: 26429962
    [Abstract] [Full Text] [Related]

  • 19. Antiepidermal growth factor variant III scFv fragment: effect of radioiodination method on tumor targeting and normal tissue clearance.
    Shankar S, Vaidyanathan G, Kuan CT, Bigner DD, Zalutsky MR.
    Nucl Med Biol; 2006 Jan 05; 33(1):101-10. PubMed ID: 16459265
    [Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 10.